Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Clinical Research
  • Published:

Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study

Prostate Cancer and Prostatic Diseases volume 23, pages 356–363 (2020)Cite this article

Subjects

Abstract

Purpose

To investigate the effectiveness and safety of SoracteLite™—transperineal percutaneous laser ablation (TPLA) in the treatment of patients with symptomatic benign prostatic hyperplasia (BPH) at 6 and 12 months follow-up.

Methods

Patients with urinary symptoms secondary to BPH underwent TPLA under local anesthesia in four centers. Under US guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment was performed with diode laser operating at 1064 nm changing the illumination time according to prostate size. The primary end-points of this study were change in IPSS, PVR, Qmax, QoL, and prostatic volume at 6 an 12 months from SoracteLiteTM TPLA treatment. Secondary end-point was the assessment of complications.

Results

Analysis was performed on data 160 patients (mean age 69.8 ± 9.6 years) with at least 6 months follow and of 83 patients (mean age 67.9 ± 8.7 years) with at least 12 months follow-up. At 6 months, IPSS improved from 22.5 ± 5.1 to 7.7 ± 3.3 (P < 0.001), PVR from 89.5 ± 84.6 to 27.2 ± 44.5 ml (P < 0.001), Qmax from 8.0 ± 3.8 to 14.3 ± 3.9 ml/s (P < 0.001), QoL from 4.5 ± 1.1 to 1.8 ± 1.0 (P < 0.001), volume from 75.0 ± 32.4 to 60.3 ± 24.5 ml (P < 0.001). At 12 months, IPSS improved from 22.5 ± 4.5 to 7.0 ± 2.9 (P < 0.001), PVR from 71.7 ± 93.9 to 17.8 ± 51.0 ml (P < 0.001), Qmax from 8.6 ± 5.2 to 15.0 ± 4.0 ml/s (P < 0.001), QoL from 4.2 ± 0.6 to 1.6 ± 0.9 (P < 0.001), volume from 87.9 ± 31.6 to 58.8 ± 22.9 ml (P < 0.001). 7/160 (4.3%) grade I and 1/160 (0.6%) grade III complication occurred.

Conclusions

SoracteLite™ TPLA allows significant improvement of IPSS, Qol, Qmax, PVR, and reduction of prostatic volume at 6 and 12 months.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Case of a patient with benign prostate hyperplasia treated with transperineal laser ablation.
Fig. 2: 3 T prostate MRI of a patient with benign prostate hyperplasia treated with transperineal laser ablation.
Fig. 3

Similar content being viewed by others

References

  1. Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5:212–8.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology. 2009;73:562–6.

    Article  PubMed  Google Scholar 

  3. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10:14–25.

    PubMed  PubMed Central  Google Scholar 

  4. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67:1066–96.

    Article  PubMed  Google Scholar 

  5. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol. 2006;50:969–79. discussion 980

    Article  PubMed  Google Scholar 

  6. Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006;6:14.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012;79:1111–6.

    Article  PubMed  Google Scholar 

  8. Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2015;67:704–13.

    Article  PubMed  Google Scholar 

  9. Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015;22:7772–82.

    PubMed  Google Scholar 

  10. Yildiz G, Bahouth Z, Halachmi S, Meyer G, Nativ O, Moskovitz B. Allium TPS–a new prostatic stent for the treatment of patients with benign prostatic obstruction: the first report. J Endourol. 2016;30:319–22.

    Article  PubMed  Google Scholar 

  11. El-Husseiny T, Buchholz N. Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up. J Endourol. 2011;25:477–80.

    Article  PubMed  Google Scholar 

  12. Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis. 2011;2:377–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol. 2013;189:1421–6.

    Article  CAS  PubMed  Google Scholar 

  14. Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63:496–503.

    Article  CAS  PubMed  Google Scholar 

  15. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled rezum system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111:1–9.

    Article  PubMed  Google Scholar 

  16. Schreuder SM, Scholtens AE, Reekers JA, Bipat S. The role of prostatic arterial embolization in patients with benign prostatic hyperplasia: a systematic review. Cardiovasc Interventional Radiol. 2014;37:1198–1219.

    Article  CAS  Google Scholar 

  17. Pisco J, Bilhim T, Costa NV, Ribeiro MP, Fernandes L, Oliveira AG. Safety and efficacy of prostatic artery chemoembolization for prostate cancer-initial experience. J Vasc Inter Radio. 2018;29:298–305.

    Article  Google Scholar 

  18. Yassaie O, Silverman JA, Gilling PJ. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: early results. Curr Urol Rep. 2017;18:91.

    Article  PubMed  Google Scholar 

  19. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117:923–9.

    Article  CAS  PubMed  Google Scholar 

  20. Roberts WW. Development and translation of histotripsy: current status and future directions. Curr Opin Urol. 2014;24:104–10.

    Article  PubMed  PubMed Central  Google Scholar 

  21. McCulloch P, Cook JA, Altman DG, Heneghan C, Diener MK, Group I. IDEAL framework for surgical innovation 1: the idea and development stages. Brit Med J. 2013;346:f3012.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Cardiovasc Interventional Radiol. 2017;40:1440–6.

    Article  Google Scholar 

  23. Pacella CM, Francica G, Di Lascio FM, Arienti V, Antico E, Caspani B, et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol. 2009;27:2615–21.

    Article  PubMed  Google Scholar 

  24. Pacella CM, Mauri G, Achille G, Barbaro D, Bizzarri G, De Feo P, et al. Outcomes and risk factors for complications of laser ablation for thyroid nodules: a multicenter study on 1531 patients. J Clin Endocrinol Metab. 2015;100:3903–10.

    Article  CAS  PubMed  Google Scholar 

  25. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol. 2011;29:205–10.

    Article  PubMed  Google Scholar 

  27. Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of aquablation((R)) vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol. 2018;199:1252–61.

    Article  PubMed  Google Scholar 

  28. Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol. 2013;189:S141–5.

    Article  PubMed  Google Scholar 

  29. Tan AHH, Gilling PJ, Kennett KM, Frampton C, Westemberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation ot the prostatewith transurethral resection of the perostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003;170:1270–4.

    Article  CAS  PubMed  Google Scholar 

  30. Kim KS, Choi JB, Bae WJ, Kim SJ, Cho HJ, Hong SH, et al. Comparison of photoselective vaporization versus Holmium laser enucleation for treatment of benign prostate hyperplasia in a small prostate volume. PLoS ONE. 2016;11:e0156133.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Jones P, Rai BP, Somani BK, Aboumarzouk OM. A review of thulium laser vapo-enucleation of the prostate: A novel laser-based strategy for benign prostate enlargement. Arab J Urol. 2015;13:209–11.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Roberts WW. New technologies in benign prostatic hyperplasia management. Curr Opin Urol. 2016;26:254–8.

    Article  PubMed  Google Scholar 

  33. Whelan JP, Bowen JM, Burke N, Woods EA, McIssac GP, Hopkins RB, et al. A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. Can Urol Assoc J. 2013;7:335–41.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yu H, Isaacson AJ, Burke CT. Review of current literature for prostatic artery embolization. Semin Interv Radiol. 2016;33:231–5.

    Article  Google Scholar 

  35. Gao YA, Huang Y, Zhang R, Yang YD, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate–a prospective, randomized, and controlled clinical trial. Radiology. 2014;270:920–8.

    Article  PubMed  Google Scholar 

  36. Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovascular interventional Radiol. 2016;39:44–52.

    Article  Google Scholar 

  37. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246–9.

    Article  PubMed  Google Scholar 

  38. Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, et al. GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol. 2008;54:893–901.

    Article  PubMed  Google Scholar 

  39. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-Year Results. J Urol. 2017;197:1565–72.

    Article  PubMed  Google Scholar 

  40. Yafi FA, Tallman CT, Seard ML, Jordan ML Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc). Int J Impot Res. 2018;30:209–14.

  41. Rassweiler MC, Mamoulakis C, Kenngott HG, Rassweiler J, de la Rosette J, Laguna MP. Classification and detection of errors in minimally invasive surgery. J Endourol. 2011;25:1713–21.

    Article  PubMed  Google Scholar 

  42. Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172:1926–9.

    Article  PubMed  Google Scholar 

  43. Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58:384–97.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Imaging and Interventional Radiology, Regina Apostolorum Hospital, Via San Francesco 50, 00041 Albano Laziale, Rome, Italy

    Claudio Maurizio Pacella

  2. Department of Diagnostic and Interventional Radiology, ASST Bergamoest, via Paderno 21, 24068, Seriate, Italy

    Gianluigi Patelli

  3. Urology Unit, Santa Rita Clinic, Via Appia, 83042 Atripalda, Avellino, Italy

    Gennaro Iapicca

  4. Department of Diagnostic Imaging and Interventional Radiology, Tor Vergata University, Policlinico Tor Vergata, Viale Oxford 81, 00133, Rome, Italy

    Guglielmo Manenti, Tommaso Perretta & Colleen P. Ryan

  5. iGRECO Ospedali Riuniti, Piazza Quintieri 1, 87100, Cosenza, Italy

    Renato Esposito

  6. Division of Interventional Radiology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy

    Giovanni Mauri

  7. Department of Oncology and Hemato-Oncology, Faculty of Medicine and Surgery University of Milan, Milan, Italy

    Giovanni Mauri

Authors
  1. Claudio Maurizio Pacella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianluigi Patelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gennaro Iapicca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guglielmo Manenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tommaso Perretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Colleen P. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Renato Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giovanni Mauri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Mauri.

Ethics declarations

Conflict of interest

GM, CMP and CR: consultant for Elesta SrL. All other authors have nothing to disclose.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pacella, C.M., Patelli, G., Iapicca, G. et al. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study. Prostate Cancer Prostatic Dis 23, 356–363 (2020). https://doi.org/10.1038/s41391-019-0196-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-019-0196-4

This article is cited by

Search

Advanced search

Quick links